is on the rise in ExPEC, with standard cephalosporin-based treatment losing its efficacy, raising the risk that patients progress to sepsis, septic shock, and organ failure. Sanofi's head of ...

Sanofi is paying $175 million upfront to claim ... targets extraintestinal pathogenic Escherichia coli or ‘ExPEC’, which is estimated to cause around 10 million cases of invasive disease ...